Page 391 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 26 Biology of Erythropoiesis, Erythroid Differentiation, and Maturation 320.e7

292. Teglund S, McKay C, Schuetz E, et al: Stat5a and Stat5b proteins have 316. Kralovics R, Indrak K, Stopka T, et al: Two new EPO receptor muta-
essential and nonessential, or redundant, roles in cytokine responses. tions: truncated EPO receptors are most frequently associated with
Cell 93:841, 1998. primary familial and congenital polycythemias. Blood 90:2057, 1997.
293. Bunting KD, Bradley HL, Hawley TS, et al: Reduced lymphomyeloid 317. Kralovics R, Sokol L, Prchal JT: Absence of polycythemia in a child with
repopulating activity from adult bone marrow and fetal liver of mice a unique erythropoietin receptor mutation in a family with autosomal
lacking expression of STAT5. Blood 99:479, 2002. dominant primary polycythemia. J Clin Invest 102:124, 1998.
294. Wu H, Klingmuller U, Acurio A, et al: Functional interaction of 318. Watowich SS, Xie X, Klingmuller U, et al: Erythropoietin receptor
erythropoietin and stem cell factor receptors is essential for erythroid mutations associated with familial erythrocytosis cause hypersensitivity
colony formation. Proc Natl Acad Sci USA 94:1806, 1997. to erythropoietin in the heterozygous state. Blood 94:2530, 1999.
295. Wu H, Klingmuller U, Besmer P, et al: Interaction of the erythropoietin 319. Ang SO, Chen H, Hirota K, et al: Disruption of oxygen homeostasis
and stem-cell-factor receptors. Nature 377:242, 1995. underlies congenital Chuvash polycythemia. Nat Genet 32:614, 2002.
296. Jubinsky PT, Krijanovski OI, Nathan DG, et al: The beta chain of the 320. Pastore YD, Jelinek J, Ang S, et al: Mutations in the VHL gene in
interleukin-3 receptor functionally associates with the erythropoietin sporadic apparently congenital polycythemia. Blood 101:1591, 2003.
receptor. Blood 90:1867, 1997. 321. Perrotta S, Nobili B, Ferraro M, et al: Von Hippel-Lindau-dependent
297. Mennini T, De Paola M, Bigini P, et al: Nonhematopoietic erythropoi- polycythemia is endemic on the island of Ischia: identification of a novel
etin derivatives prevent motoneuron degeneration in vitro and in vivo. cluster. Blood 107:514, 2006.
Mol Med 12:153, 2006. 322. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the
298. Savino C, Pedotti R, Baggi F, et al: Delayed administration of eryth- tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet
ropoietin and its non-erythropoietic derivatives ameliorates chronic 365:1054, 2005.
murine autoimmune encephalomyelitis. J Neuroimmunol 172:27, 323. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation
2006. leading to constitutive signalling causes polycythaemia vera. Nature
299. Erbayraktar S, de Lanerolle N, de Lotbiniere A, et al: Carbamylated 434:1144, 2005.
erythropoietin reduces radiosurgically-induced brain injury. Mol Med 324. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function muta-
12:74, 2006. tion of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779,
300. Fiordaliso F, Chimenti S, Staszewsky L, et al: A nonerythropoietic 2005.
derivative of erythropoietin protects the myocardium from ischemia- 325. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the
reperfusion injury. Proc Natl Acad Sci USA 102:2046, 2005. tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia,
301. Brines M, Cerami A: Discovering erythropoietin’s extra-hematopoietic and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387, 2005.
functions: biology and clinical promise. Kidney Int 70:246, 2006. 326. Jamieson CH, Gotlib J, Durocher JA, et al: The JAK2 V617F mutation
302. Li JP, D’Andrea AD, Lodish HF, et al: Activation of cell growth by occurs in hematopoietic stem cells in polycythemia vera and predisposes
binding of Friend spleen focus-forming virus gp55 glycoprotein to the toward erythroid differentiation. Proc Natl Acad Sci USA 103:6224,
erythropoietin receptor. Nature 343:762, 1990. 2006.
303. Yoshimura A, D’Andrea AD, Lodish HF: Friend spleen focus-forming 327. Zeuner A, Pedini F, Signore M, et al: Increased death receptor resistance
virus glycoprotein gp55 interacts with the erythropoietin receptor in and FLIPshort expression in polycythemia vera erythroid precursor
the endoplasmic reticulum and affects receptor metabolism. Proc Natl cells. Blood 107:3495, 2006.
Acad Sci USA 87:4139, 1990. 328. Staerk J, Kallin A, Demoulin JB, et al: JAK1 and Tyk2 activation by
304. D’Andrea AD: The interaction of the erythropoietin receptor and gp55. the homologous polycythemia vera JAK2 V617F mutation: cross-talk
Cancer Surv 15:19, 1992. with IGF1 receptor. J Biol Chem 280:41893, 2005.
305. Li JP, Hu HO, Niu QT, et al: Cell surface activation of the erythro- 329. Kaushansky K: Lineage-specific hematopoietic growth factors. N Engl
poietin receptor by Friend spleen focus-forming virus gp55. J Virol J Med 354:2034, 2006.
69:1714, 1995. 330. Royer Y, Staerk J, Costuleanu M, et al: Janus kinases affect throm-
306. Yoshimura A, Longmore G, Lodish HF: Point mutation in the exo- bopoietin receptor cell surface localization and stability. J Biol Chem
plasmic domain of the erythropoietin receptor resulting in hormone- 280:27251, 2005.
independent activation and tumorigenicity. Nature 348:647, 1990. 331. Wernig G, Mercher T, Okabe R, et al: Expression of Jak2V617F causes
307. Ben-David Y, Bernstein A: Friend virus-induced erythroleukemia and a polycythemia vera-like disease with associated myelofibrosis in a
the multistage nature of cancer. Cell 66:831, 1991. murine bone marrow transplant model. Blood 107:4274, 2006.
308. Budarf M, Huebner K, Emanuel B, et al: Assignment of the erythro- 332. Li J, Spensberger D, Ahn JS, et al: JAK2 V617F impairs hemato-
poietin receptor (EPOR) gene to mouse chromosome 9 and human poietic stem cell function in a conditional knock-in mouse model
chromosome 19. Genomics 8:575, 1990. of JAK2 V617F-positive essential thrombocythemia. Blood 116:1528,
309. Winkelmann JC, Penny LA, Deaven LL, et al: The gene for the human 2010.
erythropoietin receptor: analysis of the coding sequence and assignment 333. Marty C, Lacout C, Martin A, et al: Myeloproliferative neoplasm
to chromosome 19p. Blood 76:24, 1990. induced by constitutive expression of JAK2V617F in knock-in mice.
310. Ward JC, Harris KW, Penny LA, et al: A structurally abnormal eryth- Blood 116:783, 2010.
ropoietin receptor gene in a human erythroleukemia cell line. Exp 334. Scott LM, Tong W, Levine RL, et al: JAK2 exon 12 mutations in poly-
Hematol 20:371, 1992. cythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459,
311. Emanuel PD, Eaves CJ, Broudy VC, et al: Familial and congenital 2007.
polycythemia in three unrelated families. Blood 79:3019, 1992. 335. Kaushansky K: On the molecular origins of the chronic myeloprolifera-
312. Sokol L, Prchal JF, D’Andrea A, et al: Mutation in the negative regula- tive disorders: it all makes sense. Blood 105:4187, 2005.
tory element of the erythropoietin receptor gene in a case of sporadic 336. Mascarenhas J, Hoffman R: Ruxolitinib: the first FDA approved
primary polycythemia. Exp Hematol 22:447, 1994. therapy for the treatment of myelofibrosis. Clin Cancer Res 18:3008,
313. Arcasoy MO, Degar BA, Harris KW, et al: Familial erythrocytosis 2012.
associated with a short deletion in the erythropoietin receptor gene. 337. Schaub FX, Looser R, Li S, et al: Clonal analysis of TET2 and JAK2
Blood 89:4628, 1997. mutations suggests that TET2 can be a late event in the progression of
314. Sokol L, Luhovy M, Guan Y, et al: Primary familial polycythemia: a myeloproliferative neoplasms. Blood 115:2003, 2010.
frameshift mutation in the erythropoietin receptor gene and increased 338. Vainchenker W, Delhommeau F, Constantinescu SN, et al: New
sensitivity of erythroid progenitors to erythropoietin. Blood 86:15, mutations and pathogenesis of myeloproliferative neoplasms. Blood
1995. 118:1723, 2011.
315. Furukawa T, Narita M, Sakaue M, et al: Primary familial polycythaemia 339. Klampfl T, Gisslinger H, Harutyunyan AS, et al: Somatic mutations of
associated with a novel point mutation in the erythropoietin receptor. calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379,
Br J Haematol 99:222, 1997. 2013.